CN108069833B - 苯并四环衍生物及其制备方法和在医药上的应用 - Google Patents
苯并四环衍生物及其制备方法和在医药上的应用 Download PDFInfo
- Publication number
- CN108069833B CN108069833B CN201711040543.6A CN201711040543A CN108069833B CN 108069833 B CN108069833 B CN 108069833B CN 201711040543 A CN201711040543 A CN 201711040543A CN 108069833 B CN108069833 B CN 108069833B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- trien
- methylbicyclo
- octa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims description 25
- 206010002091 Anaesthesia Diseases 0.000 claims description 16
- 230000037005 anaesthesia Effects 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- -1 powder spray Substances 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000036461 convulsion Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 239000002960 lipid emulsion Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000004799 sedative–hypnotic effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000014 opioid analgesic Substances 0.000 claims description 2
- 229940005483 opioid analgesics Drugs 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 229940100692 oral suspension Drugs 0.000 claims description 2
- 229940098458 powder spray Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 239000010408 film Substances 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 abstract description 20
- 229940002612 prodrug Drugs 0.000 abstract description 20
- 239000000203 mixture Substances 0.000 abstract description 17
- 210000005036 nerve Anatomy 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 12
- 229960004134 propofol Drugs 0.000 description 12
- 230000028527 righting reflex Effects 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 10
- SUCXXEPEKGVSMC-MRVPVSSYSA-N (8R)-3-(1-cyclopropylethenyl)-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@@H]1CC2=C1C(=C(C=C2)C(=C)C3CC3)O SUCXXEPEKGVSMC-MRVPVSSYSA-N 0.000 description 9
- SUCXXEPEKGVSMC-QMMMGPOBSA-N (8S)-3-(1-cyclopropylethenyl)-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@H]1CC2=C1C(=C(C=C2)C(=C)C3CC3)O SUCXXEPEKGVSMC-QMMMGPOBSA-N 0.000 description 9
- NDRBWUAAIWYVGU-UHFFFAOYSA-N 7-methylbicyclo[4.2.0]octa-1(6),2,4-trien-5-ol Chemical compound C1=CC(O)=C2C(C)CC2=C1 NDRBWUAAIWYVGU-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- FWCGDBLRRMLOTB-BDAKNGLRSA-N (8R)-3-[(1S)-1-cyclopropylethyl]-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@@H]1CC2=C1C(=C(C=C2)[C@@H](C)C3CC3)O FWCGDBLRRMLOTB-BDAKNGLRSA-N 0.000 description 8
- DIGZOWJIJASHJI-RXMQYKEDSA-N (8R)-3-bromo-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound BrC=1C(=C2[C@@H](CC2=CC=1)C)O DIGZOWJIJASHJI-RXMQYKEDSA-N 0.000 description 8
- DIGZOWJIJASHJI-YFKPBYRVSA-N (8S)-3-bromo-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@H]1CC2=C1C(=C(C=C2)Br)O DIGZOWJIJASHJI-YFKPBYRVSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- NBHAHMHUMMWFPJ-UHFFFAOYSA-N 1-bromo-2-phenylmethoxybenzene Chemical compound BrC1=CC=CC=C1OCC1=CC=CC=C1 NBHAHMHUMMWFPJ-UHFFFAOYSA-N 0.000 description 7
- CUYILCFOQVAUJW-UHFFFAOYSA-N 5-phenylmethoxybicyclo[4.2.0]octa-1(6),2,4-trien-7-one Chemical compound C=12C(=O)CC2=CC=CC=1OCC1=CC=CC=C1 CUYILCFOQVAUJW-UHFFFAOYSA-N 0.000 description 7
- HAPLVROAUVDLFE-UHFFFAOYSA-N 7-methyl-5-phenylmethoxybicyclo[4.2.0]octa-1(6),2,4-trien-7-ol Chemical compound CC1(CC2=C1C(=CC=C2)OCC3=CC=CC=C3)O HAPLVROAUVDLFE-UHFFFAOYSA-N 0.000 description 7
- QABKNDFEKKLVKF-UHFFFAOYSA-N 8-methyl-2-phenylmethoxybicyclo[4.2.0]octa-1(6),2,4-triene Chemical compound C(C1=CC=CC=C1)OC1=C2C(CC2=CC=C1)C QABKNDFEKKLVKF-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- OERPYLUXGLBDDW-GFCCVEGCSA-N [(8R)-3-(1-cyclopropylethenyl)-8-methyl-2-bicyclo[4.2.0]octa-1(6),2,4-trienyl] 4-nitrobenzenesulfonate Chemical compound C[C@@H]1CC2=C1C(=C(C=C2)C(=C)C3CC3)OS(=O)(=O)C4=CC=C(C=C4)[N+](=O)[O-] OERPYLUXGLBDDW-GFCCVEGCSA-N 0.000 description 7
- NZXDEBGPHWRFNN-SECBINFHSA-N [(8R)-3-bromo-8-methyl-2-bicyclo[4.2.0]octa-1(6),2,4-trienyl] 4-nitrobenzenesulfonate Chemical compound C[C@@H]1CC2=C1C(=C(C=C2)Br)OS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-] NZXDEBGPHWRFNN-SECBINFHSA-N 0.000 description 7
- OERPYLUXGLBDDW-LBPRGKRZSA-N [(8S)-3-(1-cyclopropylethenyl)-8-methyl-2-bicyclo[4.2.0]octa-1(6),2,4-trienyl] 4-nitrobenzenesulfonate Chemical compound C[C@H]1CC2=C1C(=C(C=C2)C(=C)C3CC3)OS(=O)(=O)C4=CC=C(C=C4)[N+](=O)[O-] OERPYLUXGLBDDW-LBPRGKRZSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- FWCGDBLRRMLOTB-RKDXNWHRSA-N (8R)-3-[(1R)-1-cyclopropylethyl]-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@@H]1CC2=C1C(=C(C=C2)[C@H](C)C3CC3)O FWCGDBLRRMLOTB-RKDXNWHRSA-N 0.000 description 5
- FWCGDBLRRMLOTB-DTWKUNHWSA-N (8S)-3-[(1R)-1-cyclopropylethyl]-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@H]1CC2=C1C(=C(C=C2)[C@H](C)C3CC3)O FWCGDBLRRMLOTB-DTWKUNHWSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DIGZOWJIJASHJI-UHFFFAOYSA-N 3-bromo-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound BrC=1C(=C2C(CC2=CC=1)C)O DIGZOWJIJASHJI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- NZXDEBGPHWRFNN-VIFPVBQESA-N [(8S)-3-bromo-8-methyl-2-bicyclo[4.2.0]octa-1(6),2,4-trienyl] 4-nitrobenzenesulfonate Chemical compound C[C@H]1CC2=C1C(=C(C=C2)Br)OS(=O)(=O)C3=CC=C(C=C3)[N+](=O)[O-] NZXDEBGPHWRFNN-VIFPVBQESA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- FWCGDBLRRMLOTB-IUCAKERBSA-N (8S)-3-[(1S)-1-cyclopropylethyl]-8-methylbicyclo[4.2.0]octa-1(6),2,4-trien-2-ol Chemical compound C[C@H]1CC2=C1C(=C(C=C2)[C@@H](C)C3CC3)O FWCGDBLRRMLOTB-IUCAKERBSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- QVNNONOFASOXQV-UHFFFAOYSA-N fospropofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O QVNNONOFASOXQV-UHFFFAOYSA-N 0.000 description 3
- 229960000239 fospropofol Drugs 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- HJRPVVNTPIEREU-UONOGXRCSA-N (5R)-7,7-difluoro-N-[(6S)-4-methyl-5-oxo-7,8-dihydro-6H-pyrazolo[1,5-a][1,3]diazepin-6-yl]-5-phenyl-5,6-dihydropyrrolo[1,2-b][1,2,4]triazole-2-carboxamide Chemical compound CN1C2=CC=NN2CC[C@H](NC(=O)C2=NN3[C@H](CC(F)(F)C3=N2)C2=CC=CC=C2)C1=O HJRPVVNTPIEREU-UONOGXRCSA-N 0.000 description 2
- QSIBOLCHBXIPOG-FZMZJTMJSA-N (5S)-5-(1,1-difluoropropyl)-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide Chemical compound CCC(F)(F)[C@@H]1CCC2=NC(=NN12)C(=O)N[C@H]1COC2=CC=CC=C2N(C)C1=O QSIBOLCHBXIPOG-FZMZJTMJSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 229920001304 Solutol HS 15 Polymers 0.000 description 2
- 150000007960 acetonitrile Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CBNBGETWKBUTEL-UHFFFAOYSA-K tripotassium;phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[K+].[K+].[K+].[O-]P([O-])([O-])=O CBNBGETWKBUTEL-UHFFFAOYSA-K 0.000 description 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- VTGIVYVOVVQLRL-UHFFFAOYSA-N 1,1-diethoxyethene Chemical group CCOC(=C)OCC VTGIVYVOVVQLRL-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种苯并四环衍生物及其制备方法和在医药上的应用,具体而言涉及如式(I)所示的苯并四环衍生物,或者其立体异构体、药学上可接受的盐或前药,其制备方法、包含其的药物组合物以及本发明化合物或组合物在中枢神经领域的用途,
Description
技术领域
本发明涉及一种式(I)所示的苯并四环衍生物,其立体异构体、药学上可用的盐、共晶或前药,其制备方法,包含其的药物组合物,以及本发明的化合物和组合物在中枢神经领域的用途。
背景技术
GABAA受体是中枢神经***中主要的抑制性神经递质受体。GABAA受体由跨膜多肽亚基的五聚体构成,19种不同的亚基组成了多种不同的GABAA受体亚型。GABAA受体涉及麻醉、抑郁、焦虑、癫痫、记忆障碍、药物依赖等多种疾病的发病机制和诊断治疗。因此,GABAA受体是药理学和临床上重要的药物作用靶点。丙泊酚及其衍生物即是一类重要的以GABAA为靶点的化合物。
丙泊酚可激活多种GABAA受体亚型,是一个临床上成熟的静脉***,广泛用于全身麻醉的诱导和维持。丙泊酚的显著药代动力学和药效学性质是起效快,维持时间短和快速可逆。然而,丙泊酚也有显而易见的局限性和缺点。据报道,约70%的病人在注射丙泊酚时有一定程度的疼痛或不适(Pascale Picard(2000).Anesthesia&Analgesia,90,963-969)。在临床上会引起低血压。同时,呼吸抑制、呼吸暂停、低氧血症等也是使用丙泊酚时不可忽视的风险。这些不良反应很大程度上阻碍了丙泊酚在一些临床病例中的应用,如心血管疾病,脑损伤和慢性低血压。
磷丙泊酚是丙泊酚的水溶性前药,缓解了丙泊酚的静脉注射部位疼痛,但由于其仍是以丙泊酚原药形式起效,因此仍存在呼吸抑制和不良的血液动力学效应的风险(CohenLB(2008).Aliment PharmacolTher,27,597)。同时磷丙泊酚还可引起感觉异常和瘙痒。
鉴于丙泊酚和磷丙泊酚的局限性和缺点,需要开发新的具有更好药代动力学和药效学特性,且有较少副作用的GABAA受体激动剂。
CN1228414描述了用于治疗抑郁、焦虑、恐怖症的苯并四元环衍生物及其与一种药学上可接受的酸的加成盐,其通式化合物结构如下:
其中Z1、Z2、Z3和Z4各自独立选自H、F、Cl、Br、I、C1-6烷基、C2-6链烯基或者C2-6炔基,X代表O。该发明与本发明的结构相差较大。
CN1323794描述了苯并四元环衍生物及其与可药用酸或碱形成的加成盐,其通式化合物结构如下:
其中:代表单键或双键;n为1-6的整数;R1和R2各自独立选自H、C1-6烷基、环烷基、芳基;X选自-CH=CH-、O、S(=O)m,m为0至2的整数或者NR3,其中R3选自H、C1-6烷基、芳基。Y表示-CH或-CH2;T表示单环或多环C3-12环烷基,其中,环烷基的碳原子之一可选择性地被一种基团取代,所述基团选自O、Se或者S(=O)p,其中p为0至2的整数、NR3,该发明与本发明的结构相差较大,不认为此专利中具体描述是本发明的一部分。
WO9615099描述了用于治疗中枢神经***疾病的化合物,其通式化合物结构如下:
其中n为0至2的整数,X选自O、S、-N(R5)-或者亚甲基,R1选自H、-NH2、-NHR5或者羟基;R2、R3各自独立选自H、-COOH、-COOR5、-CONH2、-CONHR5、-CON(R5)2、CONHSO2R5或四氮唑,R4选自H、羟基、氨基、-NHR5、CF3、C1-8烷基、C2-8烯基、C2-8炔基、C3-6环烷基、苯基或C1-4烷氧基,R5可以为H、C1-8烷基、C2-8烯基、C2-8炔基、C3-6环烷基,环A可以为部分或完全饱和芳环或药学上可用盐,该发明与本发明的结构相差较大。
发明内容
本发明的目的是提供一种结构新颖、药效更好、更安全的GABAA受体激动剂,或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药,制备方法、药物组合物以及其在中枢神经领域上的用途,以便为动物或者人类诱导或维持全身麻醉,促进镇静催眠,治疗和/或预防焦虑、恶心、呕吐、偏头痛、惊厥、癫痫、神经变性疾病以及中枢神经***相关的疾病提供更多更优的药物选择途径。
本发明提供了一种式(I)化合物或者其立体异构体、药学上可接受的盐或前药,
本发明优选方案,一种式(I)根据权利要求1所述的化合物,其中该化合物选自如下结构之一:
本发明还提供了一种药物组合物,该药物组合物包含:本发明所述的化合物或者其立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药,和一种或者多种药学上可接受的载体和/或赋形剂。
本发明还提供了一种药物组合物,该药物组合物包括:本发明所述的化合物,和一种或多种选自阿片类镇痛剂、镇静催眠剂和/或心血管药剂的治疗剂。本发明涉及的药物组合物为药学上可以接受的任一剂型,优选为脂质乳剂、注射剂、片剂、气雾剂、粉雾剂、喷雾剂、膜剂、颗粒剂、分散片、冻干粉针剂、胶囊剂、软膏剂、栓剂、乳膏剂、植入剂、糖浆剂、口服溶液剂、口服混悬剂、口服乳剂、散剂或者凝胶剂,更优选冻干粉针剂、注射剂或者脂质乳剂。
本发明的化合物或者其立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药,或者所述的药物组合物,可以作为一种GABAA受体激动剂,用于制备中枢神经领域相关药物,以便为动物或者人类诱导或维持全身麻醉,促进镇静催眠,治疗和/或预防焦虑、恶心、呕吐、偏头痛、惊厥、癫痫、神经变性疾病以及中枢神经***相关的疾病提供更多更优的药物选择途径。本发明的新型GABAA受体激动剂,它们安全范围更大,起效时间更短,更为突出的是它们以固体的形式存在,相对于丙泊酚有更好的水溶性,因此可以以非脂肪乳剂的形式给药,从而降低产生注射疼痛的可能性,同时避免了乳化剂导致的过敏反应以并降低了制剂被细菌感染的几率。本发明的化合物或者其立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶或者前药用于制备相关药物或治疗相关疾病,其药效更好,更安全。
从而,本发明还提供了通式(I)所示的化合物或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物在制备中枢神经领域的药物中的用途。
本发明优选方案,提供了一种通式(I)所示的化合物,或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物在制备中枢神经领域的药物中的用途,所述中枢神经领域的药物包括:用于诱导和维持动物或者人类的麻醉的药物,促进动物或者人类的镇静催眠的药物,或者治疗和/或预防焦虑、抑郁、失眠、恶心、呕吐、偏头痛、精神***、惊厥或者癫痫的药物,所述的动物包括哺乳动物,例如陪伴动物、动物园动物和家畜,优选马或者犬。
本发明优选方案,提供了一种通式(I)所示的化合物,或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物在制备中枢神经领域的药物中的用途,所述中枢神经领域的药物包括用于诱导和维持动物或者人类的麻醉的药物。
本发明还提供了一种诱导和维持动物或者人类的麻醉的方法,该方法包括给予动物或者人类有效量的通式(I)所示的化合物或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物。
本发明还提供了一种促进动物或者人类的镇静催眠的方法,该方法包括给予动物或者人类有效量的通式(I)所示的化合物或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物。
本发明还提供了一种治疗和/或预防动物或者人类焦虑、抑郁、失眠、恶心、呕吐、偏头痛、精神***、惊厥或者癫痫的方法,该方法包括给予动物或者人类有效量的通式(I)所示的化合物或者其所有的立体异构体、溶剂化物、代谢产物、药学上可接受的盐、共晶、前药或者包括其的药物组合物。
除非有相反的陈述,在说明书和权利要求书中使用的术语具有下述含义。
本发明所述基团和化合物中所涉及的碳、氢、氧、硫、氮或F、Cl、Br、I均包括它们的同位素情况,及本发明所述基团和化合物中所涉及的碳、氢、氧、硫或氮任选进一步被一个或多个它们对应的同位素所替代,其中碳的同位素包括12C、13C和14C,氢的同位素包括氕(H)、氘(D,又叫重氢)、氚(T,又叫超重氢),氧的同位素包括16O、17O和18O,硫的同位素包括32S、33S、34S和36S,氮的同位素包括14N和15N,氟的同位素包括17F和19F,氯的同位素包括35Cl和37Cl,溴的同位素包括79Br和81Br。
“药学上可接受的盐”或者“其药学上可接受的盐”是指本发明化合物保持游离酸或者游离碱的生物有效性和特性,且所述的游离酸通过与无毒的无机碱或者有机碱,所述的游离碱通过与无毒的无机酸或者有机酸反应获得的盐。
“药物组合物”是指一种或多种本发明所述化合物、其药学上可接受的盐或前药和其它化学组分形成的混合物,其中,“其它化学组分”是指药学上可接受的载体、赋形剂和/或一种或多种其它治疗剂。
“载体”是指不会对生物体产生明显刺激且不会消除所给予化合物的生物活性和特性的材料。
“赋形剂”是指加入到药物组合物中以促进化合物给药的惰性物质。非限制性实施例包括碳酸钙、磷酸钙、糖、淀粉、纤维素衍生物(包括微晶纤维素)、明胶、植物油、聚乙二醇类、稀释剂、成粒剂、润滑剂、粘合剂和崩解剂。
“前药”是指可经体内代谢转化为具有生物活性的本发明化合物。本发明的前药通过修饰本发明化合物中的酚基团来制备,该修饰可以通过常规的操作或者在体内被除去,而得到母体化合物。当本发明的前药被施予哺乳动物个体时,前药被割裂形成游离的羟基。
“动物”是指包括哺乳动物,例如人、陪伴动物、动物园动物和家畜,优选人、马或者犬。
“立体异构体”是指由分子中原子在空间上排列方式不同所产生的异构体,包括顺反异构体、对映异构体和构象异构体。
“任选”或“任选地”或“选择性的”或“选择性地”是指随后所述的事件或状况可以但未必发生,该描述包括其中发生该事件或状况的情况及其中未发生的情况。例如,“选择性地被烷基取代的杂环基”是指该烷基可以但未必存在,该描述包括其中杂环基被烷基取代的情况,及其中杂环基未被烷基取代的情况。
ED50(半数有效量):通过测试导致50%小鼠翻正反射丧失需要的剂量。
ED95(95%有效量):通过测试导致95%小鼠翻正反射丧失需要的剂量。
LD50(半数致死量):通过测试导致50%小鼠死亡需要的剂量。
LD5(5%致死量):通过测试导致5%小鼠死亡需要的剂量。
具体实施方式
以下通过具体实施例详细说明本发明的实施过程和产生的有益效果,旨在帮助阅读者更好地理解本发明的实质和特点,不作为对本案可实施范围的限定。
化合物的结构是通过核磁共振(NMR)或(和)质谱(MS)来确定的。NMR位移(δ)以10-6(ppm)的单位给出。NMR的测定是用(BrukerAvance III 400和BrukerAvance 300)核磁仪,测定溶剂为氘代二甲基亚砜(DMSO-d6),氘代氯仿(CDCl3),氘代甲醇(CD3OD),氘代乙腈(CD3CN),内标为四甲基硅烷(TMS)。
MS的测定用(Agilent 6120B(ESI)和Agilent 6120B(APCI))。
HPLC的测定使用安捷伦1260DAD高压液相色谱仪(Zorbax SB-C18 100×4.6mm)。
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板,薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm~0.20mm,薄层层析分离纯化产品采用的规格是0.4mm~0.5mm。
柱层析一般使用烟台黄海硅胶200~300目硅胶为载体。
本发明的己知的起始原料可以采用或按照本领域已知的方法来合成,或可购买于泰坦科技、安耐吉化学、上海德默、成都科龙化工、韶远化学科技、百灵威科技等公司。
实施例1
(S)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物1)
(S)-3-((R)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
第一步:1-苄氧基-2-溴苯(1B)
1-(benzyloxy)-2-bromobenzene
将2-溴苯酚(200.00g,1.156mol),苄溴(217.48g,1.272mol),碳酸钾(319.54g,2.312mol),碘化钾(9.60g,58mmol)用丙酮(1200ml)溶于2L三口瓶中,机械搅拌均匀,加热至回流反应10小时。降至室温后,过滤,用石油醚淋洗滤饼。滤液旋干,粗产品用柱层析(乙酸乙酯:石油醚=0/100-1/50)冲柱纯化,浓缩至干得到黄色油状1-苄氧基-2-溴苯(1B)(300g,产率98.64%)。
Ms m/z(ESI):262.9[M+H+]。
第二步:5-(苄氧基)二环[4.2.0]辛-1,3,5-三烯-7-酮(1C)
5-(benzyloxy)bicyclo[4.2.0]octa-1,3,5-trien-7-one
将1-苄氧基-2-溴苯(1B)(50g,190mmol),1,1-二乙氧基乙烯(44g,380mmol),氨基钠(30g,760mmol)用四氢呋喃(450mL)溶于单口瓶中,加热至回流反应2小时,用硅藻土过滤,滤饼用THF淋洗,滤液加至3N氯化氢冰水溶液中,保持pH值在酸性范围内,加毕,用乙酸乙酯(150mL×1)萃取,有机相用水(100ml×2),饱和食盐水(100ml×1)洗涤,干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/50-1/5)冲柱纯化,浓缩至干得到黄色固体5-(苄氧基)二环[4.2.0]辛-1,3,5-三烯-7-酮(1C)(29.5g,产率69.2%)。
Ms m/z(ESI):225.2[M+H+]。
第三步:5-(苄氧基)-7-甲基二环[4.2.0]辛-1,3,5-三烯-7-醇(1D)
5-(benzyloxy)-7-methylbicyclo[4.2.0]octa-1,3,5-trien-7-ol
5-(苄氧基)二环[4.2.0]辛-1,3,5-三烯-7-酮(1C)(118g,526mmol)用四氢呋喃(800ml)溶于三口瓶中,降温至-40℃,将甲基溴化镁(263ml,789mmol)滴加至反应液中,保持温度在-30℃至-40℃,加毕,保温反应1小时。保持温度在0℃以下,滴加饱和氯化铵水溶液淬灭反应,分液,水相用乙酸乙酯(400ml×1)萃取,合并有机相,加入无水硫酸钠干燥,过滤浓缩。粗产品用柱层析(乙酸乙酯:石油醚=1/30-1/5)冲柱纯化,浓缩至干得到5-(苄氧基)-7-甲基二环[4.2.0]辛-1,3,5-三烯-7-醇(1D)(78.7g,产率62.2%)。
1H NMR(400MHz,CDCl3)δ7.42-7.37(m,5H),7.20-7.18(dd,1H),6.78-6.75(m,2H),5.28-5.15(q,2H),4.13-4.08(dd,1H),3.32-3.16(m,2H),2.24(s,6H),1.75(s,3H).
第四步:2-(苄氧基)-8-甲基二环[4.2.0]辛-1,3,5-三烯(1E)
2-(benzyloxy)-8-methylbicyclo[4.2.0]octa-1,3,5-triene
将5-(苄氧基)-7-甲基二环[4.2.0]辛-1,3,5-三烯-7-醇(1D)(74g,308mmol)用二氯甲烷(700ml)溶于单口瓶中,用冰浴降温,再将三乙基硅烷(72g,616mmol),三氟乙酸(140g,1232mmol)滴加至反应液中,自然升至室温反应2小时。反应液用水(500ml×1),饱和碳酸氢钠水溶液(500ml×1),饱和食盐水(500ml×1)洗涤,有机相加入无水硫酸钠干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/50-1/30)冲柱纯化,浓缩至干得到无色油状2-(苄氧基)-8-甲基二环[4.2.0]辛-1,3,5-三烯(1E)(45.7g,产率66.26%)。
Ms m/z(ESI):225.2[M+H+]。
第五步:8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1F)
8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将2-(苄氧基)-8-甲基二环[4.2.0]辛-1,3,5-三烯(1E)(24g,107mmol),钯碳(2.4g,10%)用甲醇(240ml)溶于单口瓶中,加入甲酸铵(34g,535mmol),于室温下反应2小时。用硅藻土过滤,滤液浓缩,加入乙酸乙酯(100ml)溶解后,用水(100ml×2)洗涤,有机相加入无水硫酸钠干燥,过滤浓缩得到浅黄色油状8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1F)(14.4g,产率100%)。
1H NMR(400MHz,CDCl3)δ7.10-7.07(q,1H),6.69-6.67(d,1H),6.62-6.60(d,1H),4.78(s,1H),3.61-3.57(m,1H),3.35-3.30(dd,1H),2.66-2.62(dd,1H),1.45-1.43(d,3H).
第六步:(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1G)
(S)-3-bromo-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1F)(23.7g,177mmol),二异丙基胺(1.8g,17.7mmol)用二氯甲烷(200ml)溶于三口瓶中,降温至-70℃左右,溴代丁二酰亚胺(29.9g,168mmol)用二氯甲烷(1300ml)溶解后缓慢滴加至反应液中,加毕,反应2小时。反应结束后,用水(500ml×1),稀盐酸(500ml×1),水(500ml×1)洗涤有机相,有机相干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/100-1/30)冲柱纯化,浓缩至干得到白色固体3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(22g,58.5%)。经手性制备得到(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1G)。
手性制备方法:
取3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(15g)用于拆分,
制备条件:
仪器:Thar 200preparative SFC(SFC-7);
柱:ChiralCel OD,300×50mm I.D.,10μm.;
流动相:A:CO2,B:乙醇;
梯度:B 15%;
流量:180mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~2min;
样品制备:样品溶解于甲醇中制得62.5mg/ml;注射:3ml/针。
分离后得到两个光学异构体化合物1G(保留时间:1.905min,6.12g,白色固体,ee%=98.5%,),化合物2B(保留时间:2.324min,6.32g,白色固体,ee%=99.1%)。
Ms m/z(ESI):212.9[M+H+]。
1H NMR(400MHz,CDCl3)δ7.32-7.30(d,1H),6.57-6.55(d,1H),5.38(s,1H),3.61-3.57(m,1H),3.29-3.24(dd,1H),2.62-2.58(dd,1H),1.44-1.42(d,3H).
第七步:(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1H)
(S)-3-bromo-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-yl 4-nitrobenzenesulfonate
将(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1G)(5g,23.5mmol),4-硝基苯磺酰氯(5.2g,23.5mmol)用二氯甲烷(35ml)溶于单口瓶中,再将三乙胺(2.4g,23.5mmol)滴加至反应液中,于室温下反应20分钟。浓缩掉二氯甲烷,再用乙酸乙酯(50mL)溶解后用水(50mL×1),饱和碳酸氢钠(50mL×1)洗涤有机相,加入无水硫酸钠干燥,过滤浓缩得到固体,加入50mL石油醚打浆,过滤,用少量石油醚淋洗,烘干得到类白色固体(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1H)(8.32g,产率89%)。
1H NMR(400MHz,CDCl3)δ8.39-8.37(m,2H),8.16-8.14(m,2H),7.37-7.35(d,1H),6.90-6.88(d,1H),3.80-3.76(m,1H),3.33-3.32(dd,1H),2.68-2.64(dd,1H),1.46-1.44(d,3H).
第八步:(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1I)
(S)-3-(1-cyclopropylvinyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-yl 4-nitrobenzenesulfonate
将(S)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1H)(8.32g,20.9mmol),2-(1-环丙基乙烯基)-4,4,5,5-四甲基-1,3,2-二氧硼戊烷(6.08g,31.3mmol),七水合磷酸钾(12.7g,37.6mmol)用甲苯(64ml)和水(24ml)溶解于单口瓶中,用氮气置换三次,加入[1,1′-双(二苯基膦)二茂铁]二氯化钯(II)(0.832g,10%),再用氮气置换三次后,氮气保护下加热至90℃反应6小时,室温放置过夜。降至室温,用硅藻土过滤,滤液用乙酸乙酯(50mL),水(50mL)淋洗,静置分层,有机相用饱和食盐水(80ml×1)洗涤,加入无水硫酸钠干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/1000-1/100)冲柱纯化,浓缩至干得到黄色固体(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1I)(6.27g,产率77.9%)。
1H NMR(400MHz,CDCl3)δ8.33-8.31(d,2H),8.07-8.04(d,2H),7.06-7.04(d,1H),6.97-6.95(d,1H),4.63-4.56(dd,2H),3.72-3.70(m,1H),3.39-3.34(dd,1H),2.70-2.66(dd,1H),1.47-1.45(d,3H),1.30-1.25(m,1H),0.71-0.66(m,1H),0.58-0.53(m,1H),0.33-0.31(m,2H).
第九步:(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1J)
(S)-3-(1-cyclopropylvinyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(1I)(6.17g,16mmol),氢氧化钠(1.92g,48mmol)用叔丁醇(60ml)溶解,加热至80℃反应2小时。冷至室温,用1M稀盐酸调节pH值至5,用EA:PE=1:1的有机溶剂(25ml×2)萃取,合并,用饱和食盐水(25ml×2)洗涤,加入无水硫酸钠干燥,过滤浓缩,经制备(乙腈/0.1%乙酸铵)纯化得到(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1J)(0.8g,收率20%)。
1H NMR(400MHz,CDCl3)δ7.01-6.99(d,1H),6.64-6.62(d,1H),5.50(s,1H),5.24(dd,1H),4.99(dd,1H),3.60-3.57(m,1H),3.32-3.27(dd,1H),2.65-2.61(dd,1H),1.64-1.60(m,1H),1.45-1.43(d,3H),0.80-0.75(m,2H),0.56-0.52(m,2H).
第十步:(S)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物1)
(S)-3-((R)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1J)(0.8g,3.99mmol),三乙基硅烷(0.7g,5.99mmol)用二氯甲烷(10ml)溶于单口瓶中,降温至-30℃以下,将三氟乙酸(0.7g,5.99mmol)用二氯甲烷(1ml)稀释后滴加至反应液中,于-30℃以下反应2小时,升至室温反应1小时。蒸干溶剂,加入乙酸乙酯(20ml),用水(20ml)饱和食盐水(20ml)洗涤,加入无水硫酸钠干燥,过滤浓缩,手性制备得到(S)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物1)(151.76mg,收率18.8%)。
手性制备方法:
(8S)-3-(1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(0.8g)用于拆分,
制备条件:
仪器:MGⅡpreparative SFC(SFC-1);
柱:ChiralCel OJ,250×30mm I.D.,5μm.;
流动相:A:CO2,B:异丙醇;
梯度:B 10%;
流量:50mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~5min;
样品制备:样品溶解于甲醇中制得4mg/ml;注射:1ml/针。
分离后得到两个光学异构体化合物1(保留时间:4.94min,151.76mg,黄色油状,ee%=99.3%),化合物3(保留时间:5.06min,168.44mg,黄色油状,ee%=97.6%,)。
Ms m/z(ESI):201.2[M-H+]。
1H NMR(400MHz,CDCl3)δ7.14-7.12(d,1H),6.68-6.66(d,1H),4.56(s,1H),3.56(m,1H),3.31-3.26(m,1H),2.63-2.59(dd,1H),2.41-2.37(m,1H),1.45-1.44(d,3H),1.29-1.27(d,3H),1.06-1.04(m,1H),0.54-0.42(m,2H),0.21-0.17(m,2H).
实施例2
(R)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物2)
(R)-3-((R)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
第一步:(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2B)
(R)-3-bromo-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1F)(23.7g,177mmol),二异丙基胺(1.8g,17.7mmol)用二氯甲烷(200ml)溶于三口瓶中,降温至-70℃左右,溴代丁二酰亚胺(29.9g,168mmol)用二氯甲烷(1300ml)溶解后缓慢滴加至反应液中,加毕,反应2小时。反应结束后,用水(500ml×1),稀盐酸(500ml×1),水(500ml×1)洗涤有机相,有机相干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/100-1/30)冲柱纯化,浓缩至干得到白色固体3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(22g,58.5%)。经手性制备得到(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2B)。
手性制备方法:
取3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(15g)用于拆分,
制备条件:
仪器:Thar 200preparative SFC(SFC-7);
柱:ChiralCel OD,300×50mm I.D.,10μm.;
流动相:A:CO2,B:乙醇;
梯度:B 15%;
流量:180mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~2min;
样品制备:样品溶解于甲醇中制得62.5mg/ml;注射:3ml/针。
分离后得到两个光学异构体化合物1G(保留时间:1.905,6.12g,白色固体,ee%=99%),化合物2B(保留时间:2.324s,6.32g,白色固体,ee%=99%,)。
Ms m/z(ESI):212.9[M+H+]。
1H NMR(400MHz,CDCl3)δ7.32-7.30(d,1H),6.57-6.55(d,1H),3.61-3.57(m,1H),3.29-3.24(dd,1H),2.62-2.58(dd,1H),1.44-1.42(d,3H).
第二步:(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2C)
(R)-3-bromo-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-yl 4-nitrobenzenesulfonate
将(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2B)(5g,23.5mmol),4-硝基苯磺酰氯(5.2g,23.5mmol)用二氯甲烷(35ml)溶于单口瓶中,再将三乙胺(2.4g,23.5mmol)滴加至反应液中,于室温下反应20分钟。浓缩掉二氯甲烷,再用乙酸乙酯(50mL)溶解后用水(50mL×1),饱和碳酸氢钠(50mL×1)洗涤有机相,加入无水硫酸钠干燥,过滤浓缩得到固体,加入50mL石油醚打浆,过滤,用少量石油醚淋洗,烘干得到类白色固体(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2C)(8.52g,产率91.2%)。
1H NMR(400MHz,CDCl3)δ8.39-8.37(m,2H),8.16-8.14(m,2H),7.37-7.35(d,1H),6.90-6.88(d,1H),3.80-3.76(m,1H),3.33-3.32(dd,1H),2.68-2.64(dd,1H),1.46-1.44(d,3H).
第三步:(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2D)
(R)-3-(1-cyclopropylvinyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-yl 4-nitrobenzenesulfonate
将(R)-3-溴-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2C)(8.52g,20.9mmol),2-(1-环丙基乙烯基)-4,4,5,5-四甲基-1,3,2-二氧硼戊烷(6.23g,32.1mmol),七水合磷酸钾(13.0g,38.5mmol)用甲苯(64ml)和水(24ml)溶解于单口瓶中,用氮气置换三次,加入[1,1′-双(二苯基膦)二茂铁]二氯化钯(II)(0.852g,10%),再用氮气置换三次后,氮气保护下加热至90℃反应6小时,室温放置过夜。降至室温,用硅藻土过滤,滤液用乙酸乙酯(50mL),水(50mL)淋洗,静置分层,有机相用饱和食盐水(80ml×1)洗涤,加入无水硫酸钠干燥,过滤浓缩,粗产品用柱层析(乙酸乙酯:石油醚=1/1000-1/100)冲柱纯化,浓缩至干得到黄色固体(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2D)(6.32g,产率76.6%)。
1H NMR(400MHz,CDCl3)δ8.33-8.31(d,2H),8.07-8.04(d,2H),7.06-7.04(d,1H),6.97-6.95(d,1H),4.63-4.56(dd,2H),3.72-3.70(m,1H),3.39-3.34(dd,1H),2.70-2.66(dd,1H),1.47-1.45(d,3H),1.30-1.25(m,1H),0.71-0.66(m,1H),0.58-0.53(m,1H),0.33-0.31(m,2H).
第四步:(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2E)
(R)-3-(1-cyclopropylvinyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-基4-硝基苯磺酸酯(2D)(6.32g,16.4mmol),氢氧化钠(1.97g,49.2mmol)用叔丁醇(60ml)溶解,加热至80℃反应2小时。冷至室温,用1M稀盐酸调节pH值至5,用EA:PE=1:1的有机溶剂(25ml×2)萃取,合并,用饱和食盐水(25ml×2)洗涤,加入无水硫酸钠干燥,过滤浓缩,经制备(乙腈/0.1%乙酸铵)纯化得到(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2E)(1.1g,收率33%)。
1H NMR(400MHz,CDCl3)δ7.01-6.99(d,1H),6.64-6.62(d,1H),5.50(s,1H),5.24(dd,1H),4.99(dd,1H),3.60-3.57(m,1H),3.32-3.27(dd,1H),2.65-2.61(dd,1H),1.64-1.60(m,1H),1.45-1.43(d,3H),0.80-0.75(m,2H),0.56-0.52(m,2H).
第五步:(R)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物2)
(R)-3-((R)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2E)(1.1g,5.5mmol),三乙基硅烷(0.96g,8.2mmol)用二氯甲烷(10ml)溶于单口瓶中,降温至-30℃以下,将三氟乙酸(0.94g,8.2mmol)用二氯甲烷(1ml)稀释后滴加至反应液中,于-30℃以下反应2小时,升至室温反应1小时。蒸干溶剂,加入乙酸乙酯(20ml),用水(20ml)饱和食盐水(20ml)洗涤,加入无水硫酸钠干燥,过滤浓缩,手性制备得到(R)-3-((R)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物2)(289.65mg,收率26%)。
手性制备方法:
(8R)-3-(1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1.1g)用于拆分,
制备条件:
仪器:Thar 350preparative SFC(SFC-6);
柱:ChiralPak AD,300×50mm I.D.,10μm.;
流动相:A:CO2,B:异丙醇;
梯度:B 20%;
流量:200mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~2.6min;
样品制备:样品溶解于甲醇中制得3.7mg/ml;注射:3ml/针。
分离后得到两个光学异构体化合物2(保留时间:4.24min,289.65mg,黄色油状,ee%=100%),化合物4(保留时间:4.39min,208.75mg,黄色油状,ee%=98.9%)。Ms m/z(ESI):201.2[M-H+]。
1H NMR(400MHz,CDCl3)δ7.14-7.12(d,1H),6.68-6.66(d,1H),4.56(s,1H),3.56(m,1H),3.31-3.26(m,1H),2.63-2.59(dd,1H),2.41-2.37(m,1H),1.45-1.44(d,3H),1.29-1.27(d,3H),1.06-1.04(m,1H),0.54-0.42(m,2H),0.21-0.17(m,2H).
实施例3
(S)-3-((S)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物3)
(S)-3-((S)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(S)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1J)(0.8g,3.99mmol),三乙基硅烷(0.7g,5.99mmol)用二氯甲烷(10ml)溶于单口瓶中,降温至-30℃以下,将三氟乙酸(0.7g,5.99mmol)用二氯甲烷(1ml)稀释后滴加至反应液中,于-30℃以下反应2小时,升至室温反应1小时。蒸干溶剂,加入乙酸乙酯(20ml),用水(20ml)饱和食盐水(20ml)洗涤,加入无水硫酸钠干燥,过滤浓缩,手性制备得到(S)-3-((S)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物3)(168.44mg,收率20.8%)。
手性制备方法:
(8S)-3-(1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(0.8g)用于拆分,
制备条件:
仪器:MGⅡpreparative SFC(SFC-1);
柱:ChiralCel OJ,250×30mm I.D.,5μm.;
流动相:A:CO2,B:异丙醇;
梯度:B 10%;
流量:50mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~5min;
样品制备:样品溶解于甲醇中制得4mg/ml;注射:1ml/针。
分离后得到两个光学异构体化合物1(保留时间:4.94min,151.76mg,黄色油状,ee%=99.3%),化合物3(保留时间:5.06min,168.44mg,黄色油状,ee%=97.6%)。
Ms m/z(ESI):201.2[M-H+]。
1H NMR(400MHz,CDCl3)δ7.14-7.12(d,1H),6.68-6.66(d,1H),4.56(s,1H),3.56(m,1H),3.31-3.26(m,1H),2.63-2.59(dd,1H),2.41-2.37(m,1H),1.45-1.44(d,3H),1.29-1.27(d,3H),1.06-1.04(m,1H),0.54-0.42(m,2H),0.21-0.17(m,2H).
实施例4
(R)-3-((S)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物4)
(R)-3-((S)-1-cyclopropylethyl)-8-methylbicyclo[4.2.0]octa-1,3,5-trien-2-ol
将(R)-3-(1-环丙基乙烯基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(2E)(1.1g,5.5mmol),三乙基硅烷(0.96g,8.2mmol)用二氯甲烷(10ml)溶于单口瓶中,降温至-30℃以下,将三氟乙酸(0.94g,8.2mmol)用二氯甲烷(1ml)稀释后滴加至反应液中,于-30℃以下反应2小时,升至室温反应1小时。蒸干溶剂,加入乙酸乙酯(20ml),用水(20ml)饱和食盐水(20ml)洗涤,加入无水硫酸钠干燥,过滤浓缩,手性制备得到(R)-3-((S)-1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(化合物4)(208.75mg,收率19%)。
手性制备方法:
(8R)-3-(1-环丙基乙基)-8-甲基二环[4.2.0]辛-1,3,5-三烯-2-醇(1.1g)用于拆分,
制备条件:
仪器:Thar 350preparative SFC(SFC-6);
柱:ChiralPak AD,300×50mm I.D.,10μm.;
流动相:A:CO2,B:异丙醇;
梯度:B 20%;
流量:200mL/min;
背压:100bar;
柱温:38℃;波长:220nm;
周期:~2.6min;
样品制备:样品溶解于甲醇中制得3.7mg/ml;注射:3ml/针。
分离后得到两个光学异构体化合物2(保留时间:4.24min,289.65mg,黄色油状,ee%=100%),化合物4(保留时间:4.39min,208.75mg,黄色油状,ee%=98.9%)。
Ms m/z(ESI):201.2[M-H+]。
1H NMR(400MHz,CDCl3)δ7.14-7.12(d,1H),6.68-6.66(d,1H),4.56(s,1H),3.56(m,1H),3.31-3.26(m,1H),2.63-2.59(dd,1H),2.41-2.37(m,1H),1.45-1.44(d,3H),1.29-1.27(d,3H),1.06-1.04(m,1H),0.54-0.42(m,2H),0.21-0.17(m,2H).
生物测试
1、小鼠翻正反射实验
试验动物:ICR小鼠,雌雄各半,共240只,体重18-22g,6-8周龄,由成
都达硕实验动物有限责任公司提供,生产许可证号为scxk(川)2015-030。
化合物及配置:准确称取一定量受试化合物,DMSO溶解,加入solutol HS-15增溶,再加入生理盐水,旋涡混合即可。DMSO终浓度为10%,solutolHS-15终浓度为10%。临用前新鲜配制。
试验方法:试验前一天,动物禁食不禁水12小时。试验当天,根据动物体重随机分组,雌雄各半,每组8只。静脉给予各受试化合物溶液,给药体积为10ml/kg,剂量范围为1-60mg/kg,根据给药后动物翻正反射消失情况调整。记录翻正反射消失时间、翻正反射恢复时间及行走时间。给药后到翻正反射消失的时间为麻醉诱导时间,翻正反射消失到翻正反射恢复的时间为麻醉持续时间,翻正反射恢复到行走的时间为麻醉恢复时间,以麻醉诱导时间、麻醉维持时间、翻正反射消失率等指标评价麻醉效果。
翻正反射消失时间:翻正反射消失,使之处于仰卧位并能够持续60s的时间;
翻正反射恢复时间:翻正反射能力恢复,使之处于仰卧位翻正时间小于2s。
行走时间:翻正反射能力恢复至出现自主的向前运动,四肢肌张力恢复的时间。
数据处理与分析:
用microsoft excel软件计算各组动物翻正反射消失率、麻醉诱导时间、麻醉持续时间、麻醉恢复时间和死亡率。
用Graphpad Prism 6.0拟合剂量-翻正反射消失率曲线、剂量-死亡率曲线,计算翻正反射半数有效剂量(ED50)。
实验结果见表1,表2。
表1小鼠翻正反射实验数据
结论:本发明化合物具有较好的活性,起效时间快,麻醉时间长。
Claims (7)
3.一种药物组合物,所述药物组合物包含:权利要求1-2任一项所述的化合物或者其立体异构体、药学上可接受的盐,和一种或者多种药学上可接受的载体和/或赋形剂。
4.一种药物组合物,所述药物组合物包含:权利要求1-2中任一项所述的化合物或者其立体异构体、药学上可接受的盐,和一种或多种选自阿片类镇痛剂、镇静催眠剂或者心血管药剂的治疗剂。
5.根据权利要求3或者4所述的药物组合物,该药物组合物为药学上可以接受的任一剂型。
6.根据权利要求5所述的药物组合物,其中所述剂型选自脂质乳剂、注射剂、片剂、气雾剂、粉雾剂、喷雾剂、膜剂、颗粒剂、胶囊剂、软膏剂、栓剂、乳膏剂、植入剂、糖浆剂、口服溶液剂、口服混悬剂、口服乳剂、分散片剂、冻干粉针剂、散剂或者凝胶剂。
7.权利要求1-2中任一项所述的化合物或者其立体异构体、药学上可接受的盐,或者权利要求3-6中任一项所述的药物组合物在制备中枢神经领域的药物中的用途,所述中枢神经领域的药物选自用于诱导和维持动物或者人类的麻醉的药物,促进动物或者人类的镇静催眠的药物,或者治疗和/或预防焦虑、抑郁、失眠、恶心、呕吐、偏头痛、精神***、惊厥、癫痫的药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016110062215 | 2016-11-15 | ||
CN201611006221 | 2016-11-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108069833A CN108069833A (zh) | 2018-05-25 |
CN108069833B true CN108069833B (zh) | 2020-11-06 |
Family
ID=62159523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711040543.6A Active CN108069833B (zh) | 2016-11-15 | 2017-11-01 | 苯并四环衍生物及其制备方法和在医药上的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108069833B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101151234A (zh) * | 2005-03-31 | 2008-03-26 | 三共农业株式会社 | 环丙基苯酚衍生物的制造方法 |
WO2014180305A1 (zh) * | 2013-05-09 | 2014-11-13 | 四川海思科制药有限公司 | 苯酚衍生物及其制备方法和在医药上的应用 |
WO2014180327A1 (zh) * | 2013-05-10 | 2014-11-13 | 四川海思科制药有限公司 | 苯酚衍生物及其制备方法和在医药上的应用 |
WO2016034079A1 (zh) * | 2014-09-04 | 2016-03-10 | 四川海思科制药有限公司 | 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途 |
-
2017
- 2017-11-01 CN CN201711040543.6A patent/CN108069833B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101151234A (zh) * | 2005-03-31 | 2008-03-26 | 三共农业株式会社 | 环丙基苯酚衍生物的制造方法 |
WO2014180305A1 (zh) * | 2013-05-09 | 2014-11-13 | 四川海思科制药有限公司 | 苯酚衍生物及其制备方法和在医药上的应用 |
WO2014180327A1 (zh) * | 2013-05-10 | 2014-11-13 | 四川海思科制药有限公司 | 苯酚衍生物及其制备方法和在医药上的应用 |
WO2016034079A1 (zh) * | 2014-09-04 | 2016-03-10 | 四川海思科制药有限公司 | 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN108069833A (zh) | 2018-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1908753B1 (en) | Novel heterocyclidene acetamide derivative | |
US20040248983A1 (en) | N-arylphenylacetamide derivatives and medicinal compositions containing the same | |
TW202115038A (zh) | 苯甲醯胺稠芳環類衍生物、其製備方法及其在醫藥上的應用 | |
RU2016116516A (ru) | Композиции ингибиторов тирозинкиназных рецепторов белков | |
US11654198B2 (en) | Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia | |
JPH02295924A (ja) | 刺激性アミノ酸拮抗剤 | |
CN112566909A (zh) | 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途 | |
CA2781436A1 (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
EP4337666A1 (en) | Psilocybin and psilocin conjugates for treatment of mental illnesses | |
JPH05186432A (ja) | イミダゾール化合物、その製造方法及びその使用方法 | |
US20220162169A1 (en) | 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine | |
US20200277278A1 (en) | Deuterium Atom-Substituted Indole Formamide Derivative, Preparation Method Therefor, and Medical Applications Thereof | |
JP2004501901A (ja) | イミノピリミジン系nmdanr2b受容体拮抗薬 | |
TW202132249A (zh) | ***二酚型***素化合物 | |
CN108069833B (zh) | 苯并四环衍生物及其制备方法和在医药上的应用 | |
AT391320B (de) | Piperazincarbonsaeure, ihre herstellung und diese enthaltende arzneimittel | |
RU2300532C2 (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция | |
WO2022129909A1 (en) | Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof | |
WO2019215937A1 (ja) | テトラヒドロナフチルウレア誘導体の結晶 | |
EP3722299A1 (en) | Anti-pain compound and preparation method therefor | |
CN111247148B (zh) | Wnt通路调节剂 | |
WO2023054006A1 (ja) | オピオイド受容体拮抗剤及び医薬組成物 | |
WO2021160134A1 (zh) | 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型 | |
WO2022022646A1 (zh) | 含硒五元杂芳环化合物 | |
JP7134983B2 (ja) | テトラヒドロナフチルウレア誘導体の結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240115 Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region Patentee after: Tibet Haisike Pharmaceutical Co.,Ltd. Address before: 611130 No.136 Baili Road, Wenjiang cross strait science and Technology Park, Chengdu, Sichuan Patentee before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |